The transplant is only the start of treatment
A donor organ carries biological markers that differ from the recipient’s. Immune cells can recognize those differences and coordinate an attack, damaging the organ’s blood vessels and tissue. Anti-rejection medicines interrupt parts of that response; they do not make the donor organ biologically identical to the patient’s own.
That distinction shapes care long after surgery. Doctors adjust drug combinations to suppress rejection while preserving enough immune defense to fight infections and other threats. Too little suppression can put the transplant at risk; too much can leave the patient vulnerable. Regular appointments and blood tests help clinicians check drug levels, watch for side effects, and respond when the balance shifts.
A recurring cost, not a one-time procedure
The transplant operation is a major expense, but medication and monitoring become ongoing needs. Patients may face recurring pharmacy costs, laboratory tests, and clinic visits, while health systems must provide follow-up care for years. The burden can be especially difficult when insurance coverage changes or a person cannot reliably reach a pharmacy or transplant clinic.
Skipping or interrupting medication is not simply a matter of missing a routine prescription: the immune response can damage a functioning organ. The success of a transplant therefore depends not only on surgery, but on sustained access to treatment and follow-up.
